Prior to joining Novo Nordisk Dr Schindler was vice president, head
of cardiovascular and metabolic diseases innovative medicines (CVMD
iMed) at AstraZeneca, Sweden. From 2009-2012 he was head of research
at (OSI) Prosidion, Oxford, UK. From 2000-2008 he worked in various
leadership roles at Boehringer Ingelheim, Germany after having started
his career with Glaxo Wellcome/GSK, UK in 1997. Dr Schindler holds a
PhD from the University of Cambridge, UK.